Soteria Launches with $42 Million in Series A Financing

Soteria Biotherapeutics, Inc. a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, today announced a $42 million Series A financing led by Roche Venture Fund and 5AM Ventures with participation from other leading investors, including M Ventures, Novartis Venture Fund and Alexandria Venture Investments.

Soteria was founded in 2018 by Professor Jim Wells and co-founders Zach Hill and Alex Martinko from the Wells Lab with technology licensed from UC San Francisco. Zach Hill was also a graduate of the Innovation Ventures Startup 101 prior to launching Soteria.